A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs AAV2 GDNF (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2016 Planned End Date changed from 1 Jan 2018 to 1 Dec 2027.
- 14 Dec 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2025.